Vitamin D and prostate cancer risk - A less sunny outlook?

Journal of the National Cancer Institute

Volumn 100, Issue 11, 2008, Pages 759-761

  Mucci, Lorelei A ^a,b   Spiegelman, Donna ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; CALCITRIOL; PROSTATE SPECIFIC ANTIGEN; VITAMIN D;

BREAST CANCER; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; COLORECTAL CANCER; DISEASE ASSOCIATION; DRUG MEGADOSE; EDITORIAL; HUMAN; MORTALITY; OBESITY; PANCREAS CANCER; PREVALENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; SUN EXPOSURE; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN D METABOLISM; VITAMIN SUPPLEMENTATION;

HUMANS; INCIDENCE; MALE; MASS SCREENING; PREVALENCE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; UNITED STATES; VITAMIN D;

EID: 44949233177     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djn164     Document Type: Editorial

References (34)

1. Zadshir A, Tareen N, Pan D, Norris K, Martins D. The prevalence of hypovitaminosis D among US adults: data from the NHANES III. Ethn Dis.. 2005;15(4 suppl 5):S5-97-S5-101.
2. Hirani V, Primatesta P. Vitamin D concentrations among people aged 65 years and over living in private households and institutions in England: population survey. Age Ageing. 2005;34(5):485-491.
3. Harris SS, Dawson-Hughes B. Seasonal changes in plasma 25-hydroxyvitamin D concentrations of young American black and white women. Am J Clin Nutr. 1998;67:1232-1236.
4. Vilarrasa N, Maravall J, Estepa A, et al. Low 25-hydroxyvitamin D concentrations in obese women: their clinical signifi cance and relationship with anthropometric and body composition variables. J Endocrinol Invest. 2007;30(8):653-658.
5. Rockell JE, Green TJ, Skeaff CM, et al. Season and ethnicity are determinants of serum 25-hydroxyvitamin D concentrations in New Zealand children aged 5-14 y. J Nutr. 2005;135(11):2602-2608.
6. Autier P, Gandini S. Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials. Arch Intern Med. 2007;167:1730-1737.
7. Holick MF. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers and cardiovascular disease. Am J Clin Nutr. 2004;80(6 suppl):1678S-1688S.
8. Forman JD, Giovannucci E, Holmes MD, et al. Plasma 25-hydroxyvitamin D levels and risk of incident hypertension. Hypertension. 2007;49:1063-1069.
9. Bischoff-Ferrari HA, Willett WC, Wong JB, Giovannucci E, Dietrich T, Dawson-Hughes B. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA. 2005;293:2257-2264.
10. Garland CF, Garland FC. Do sunlight and vitamin D reduce the likelihood of colon cancer? Int J Epidemiol. 1980;9:227-231.
11. Giovannucci E, Liu Y, Rimm EB, et al. Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. J Natl Cancer Inst. 2006;98:451-459.
12. Giovannucci E. Vitamin D and cancer incidence in the Harvard cohorts [published online ahead of print]. Ann Epidemiol. 2008.
13. Chan JM, Giovannucci E, Andersson SO, Yuen J, Adami HO, Wolk A. Dairy products, calcium, phosphorus, vitamin D and risk of prostate cancer. Cancer Causes Control. 1998;9:559-564.
14. Jacobs ET, Guiliano AR, Martinez ME, Hollis BW, Reid ME, Marshall JR. Plasma levels of 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D and the risk of prostate cancer. J Steroid Biochem Mol Biol. 2004;89-90(1-5):533-537.
15. Li H, Stampfer MJ, Hollis BW, et al. A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer. PLOS Med. 2007;4(3):e103.
16. Giovannucci E, Liu Y, Platz EA, Stampfer MJ, Willett WC. Risk factors for prostate cancer incidence and progression in the health professionals follow-up study. Int J Cancer. 2007;121(7):1571-1578.
17. Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA. 2005;293(17):2095-2101.
18. Ahn J, Peters U, Albanes D, et al. Serum vitamin D concentrations and prostate cancer risk: a nested case-control study. J Natl Cancer Inst. 2008;100(11):796-804.
19. Trivedi DP, Doll R, Khaw KT. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ. 2003;326(7387):469.
20. Grant AM, Anderson FH, Avenell A, et al. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial. Lancet. 2005;365(9471):1621-1628.
21. Lips P, Graafmans WC, Ooms ME, Bezemer PD, Bouter LM. Vitamin D supplementation and fracture incidence in elderly persons - a randomized, placebo-controlled clinical trial. Ann Intern Med. 1996;124(4):400-406.
22. Platz EA, Leitzmann MF, Hollis BW, Willett WC, Giovannucci E. Plasma 1,25-dihydroxy- and 25-hydroxyvitamin D and subsequent risk of prostate cancer. Cancer Causes and Control. 2004;15(3):255-265.
23. Rosner B, Spiegelman D, Willett WC. Correction of logistic regression relative risk estimates and confi dence intervals for random within-person measurement error. Am J Epidemiol. 1992;136(11):1400-1413.
24. Drews CD, Flanders WD, Kosinski AS. Use of 2 data sources to estimate odds ratios in case-control studies. Epidemiology. 1993;4(4):327-335.
25. Hertzmark E, Spiegelman D. %relibpls8 SAS macro for adjusting relative risk estimates for bias due to random within-person variation. http://www.hsph.harvard.edu/faculty/spiegelman/relibpls8.html.
26. Greenland S. Avoiding power loss associated with categorization and ordinal scores in dose-response and trend analysis. Epidemiology. 1995;6(4):450-454.
27. Greenland S. Dose-response and trend analysis in epidemiology - alternatives to categorical analysis. Epidemiology. 1995;6(4):356-365.
28. Durrleman S, Simon R. Flexible regression models with cubic splines. Stat Med. 1989;8(5):551-561.
29. Govindarajulu U, Spiegelman D, Thurston S, Eisen E. Comparing smoothing techniques for modeling exposure-response curves in Cox models. Stat Med. 2007;26:3735-3752.
30. Hertzmark E, Spiegelman D. %lgtphcurv8 SAS macro for smoothing logistic and Cox regression models. http://www.hsph.harvard.edu/faculty/spiegelman/ lgtphcurv8.html. Accessed May 6, 2008.
31. Greenland S, Longnecker MP. Methods for trend estimation from summarized dose-response data, with applications to metaanalysis. Am J Epidemiol. 1992;135(11):1301-1309.
32. Orsini N, Bellocco R, Greenland S. Generalized least squares for trend estimation of summarized dose-response data. Stata J. 2006;6(1):40-57.
33. Chen TC, Wang L, Whitlatch LW, Flanagan JN, Holick MF. Prostatic 25-hydroxyvitamin D-1alpha-hydroxylase and its implication in prostate cancer. J Cell Biochem. 2003;88(2):315-322.
34. Beer TM, Ryan CW, Venner PM, et al. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J Clin Oncol. 2007;25(6):669-674.